Sun Pharma to extend MFN pricing to US state Medicaid programmes

Sun Pharma ranks second in US dermatology by prescriptions, with key brands including Ilumya for plaque psoriasis and Winlevi for acne. Recent US launches include Leqselvi for severe alopecia areata and Unloxcyt for advanced cutaneous squamous cell carcinoma, strengthening its presence in dermatology and cutaneous oncology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4aMSKxO
via IFTTT